Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncosec Medical (ONCS)

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,604
  • Shares Outstanding, K 10,695
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,280 K
  • 60-Month Beta 2.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/19
See More
  • Average Estimate -0.75
  • Number of Estimates 1
  • High Estimate -0.75
  • Low Estimate -0.75
  • Prior Year -1.40
  • Growth Rate Est. (year over year) +46.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.80 +12.22%
on 11/15/19
2.50 -19.20%
on 12/12/19
+0.08 (+4.12%)
since 11/13/19
3-Month
1.60 +26.25%
on 10/09/19
2.65 -23.77%
on 10/22/19
+0.03 (+1.51%)
since 09/13/19
52-Week
1.60 +26.25%
on 10/09/19
9.50 -78.74%
on 01/31/19
-5.93 (-74.59%)
since 12/13/18

Most Recent Stories

More News
OncoSec Presents Interim Data of 28.5% Objective Response Rate (ORR) from Ongoing KEYNOTE-890 Study Evaluating TAVO(TM) in Combination with KEYTRUDA® for Heavily Pretreated, Late-Stage, Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio Breast Cancer Symposium

OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced interim results from KEYNOTE-890, an ongoing Phase 2 study of...

ONCS : 2.02 (-16.18%)
OncoSec CEO Sends Letter to Fellow Shareholders

--Immediate $30 Million Cash Infusion at a Premium Provides Pathway to Unlock Value of TAVO(TM) and OncoSec's Entire Platform

ONCS : 2.02 (-16.18%)
OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value

--Encourages Shareholders to Vote "FOR" the CGP/Sirtex Transaction on the WHITE Proxy Card Today

SXMDF : 24.9000 (+5.73%)
ONCS : 2.02 (-16.18%)
Alpha Holdings Urges OncoSec Stockholders to Vote Against China Grand Takeover Proposal at Special Meeting of Stockholders

--Files Definitive Proxy Materials with SEC

ONCS : 2.02 (-16.18%)
Alpha Holdings Comments on OncoSec's Inability to Defend China Grand Takeover

Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today issued the following...

ONCS : 2.02 (-16.18%)
OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO(TM) and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced it will present interim efficacy, immunological and safety...

ONCS : 2.02 (-16.18%)
OncoSec Comments on Disturbing Elements of Alpha Holdings' Revised Preliminary Proxy Filing

--OncoSec Believes Alpha's Proposed Voting Scheme Could Disenfranchise Shareholders and Potentially Violate Federal Securities Laws

ONCS : 2.02 (-16.18%)
OncoSec Sets the Record Straight on Alpha Holdings' False and Misleading Statements

--Alpha is Attempting to Interfere with Shareholder Democracy by Suing to Prevent a Shareholder Vote on the Transaction

ONCS : 2.02 (-16.18%)
Alpha Holdings Wins in Nevada Court and Comments on OncoSec's Cynical Attempt to Push Through China Grand Deal

--Court Denies OncoSec's Motion to Dismiss Stockholder Class Action

ONCS : 2.02 (-16.18%)
OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer...

ONCS : 2.02 (-16.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ONCS with:

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 2.61
1st Resistance Point 2.32
Last Price 2.02
1st Support Level 1.84
2nd Support Level 1.65

See More

52-Week High 9.50
Fibonacci 61.8% 6.48
Fibonacci 50% 5.55
Fibonacci 38.2% 4.62
Last Price 2.02
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar